Paragon Therapeutics, Inc. | LinkedIn (original) (raw)

About us

Paragon Therapeutics, Inc. is a biotechnology company dedicated to discovering and developing best-in-class biologics for patients with high unmet needs. Our collaborative team of innovators has deep expertise in biologics engineering and development and a passion to tackle some of the toughest disease areas and improve quality of life for patients. If you’re eager to help shape the next generation of biologic treatments, join us! Check out our open positions and learn more at paragontherapeutics.com.

Industry

Biotechnology

Company size

11-50 employees

Headquarters

Waltham, MA

Type

Privately Held

Founded

2021

Locations

Employees at Paragon Therapeutics, Inc.

Updates

We applaud our partners at Apogee Therapeutics for their continued advancements in developing potentially transformative therapies for I&I! Excited to see the selection of a development candidate for APG333 and acceleration of Phase 1 start in late '24/early '25 toward delivering a best-in-class combination efficacy across multiple respiratory indications. Looking forward to their R&D day on December 2nd! Read the release below.
Today, we reported Q3 2024 financial results and updates from across our pipeline. We continue to execute across our portfolio and advance potentially transformative therapies for patients living with I&I diseases. Read through key updates below and learn more here. https://lnkd.in/e-J6ZUGH
Congratulations to our partner, Spyre Therapeutics, on the positive interim Phase 1 data for SPY001 in healthy volunteers! This first-in-human data supports the program and pipeline’s potential to transform treatment for IBD. We look forward to more exciting milestones over the coming year! See the press release below for more details.
Earlier today, we announced positive interim Phase 1 results for our lead clinical asset SPY001. A novel half-life extended anti-α4β7 antibody, SPY001 demonstrated a half-life of >90 days supporting the potential for twice-annual dosing compared to existing therapies which require dosing every two weeks. SPY001 was well-tolerated with a favorable safety profile consistent with other drugs in its class. Based on these results, we plan to initiate a Phase 2 trial in mid-2025. Be sure to check back soon for additional information. You can read the full press release and forward-looking statement disclosures here: https://lnkd.in/ekNXekaKA webcast and conference call are scheduled for 8:00am ET today. For details, visit https://ir.spyre.com/ #IBD #BioTech
Congratulations to our colleagues at Jade Biosciences on the merger agreement with Aerovate Therapeutics, Inc. and the $300M concurrent private financing announced earlier today. The combined company will advance a portfolio of transformative therapies for patients with autoimmune disease. Congratulations to Tom Frohlich, Andrew King, and the entire team on this milestone! More details below.#Financing #Biotech #Merger #Autoimmune
Jade Biosciences is merging with Aerovate Therapeutics to create a company focused on advancing breakthrough therapies for #autoimmune diseases. With our lead program, JADE-001, anticipated to move into the clinic in the second half of 2025 and strong financial backing, we’re well positioned to make meaningful progress with our programs. Read our press release for all the details: https://lnkd.in/gnKy4NVC
We are excited to share that Crescent Biopharma, the fifth company founded based on assets discovered by Paragon, has entered into an acquisition agreement with GlycoMimetics and announced a $200M concurrent private financing. The combined company will advance a portfolio of novel biologics precision engineered to improve outcomes for patients with solid tumors. Read the full release below. Congratulations to Interim CEO Jonathan Violin and CBO Chris Doughty on this milestone #Biotech #Merger #Oncology
📢 NEWS: GlycoMimetics has announced an agreement to acquire Crescent Biopharma and advance Crescent’s portfolio of novel biologics precision engineered to improve outcomes for patients with solid tumors — delivering superior efficacy to the current gold standard. Upon completion of the merger, the unified company will operate as Crescent, progressing lead assets CR-001, a cooperative PD-1 x VEGF bispecific antibody and CR-002, an antibody-drug conjugate for an undisclosed target with a topoisomerase inhibitor payload that may offer best-in-class efficacy. With a concurrent private financing of approximately $200 million led by Fairmount Funds Management LLC, Venrock, BVF PARTNERS, L.P, and a large investment management firm, Crescent expects to fund operations through 2027. Read the release here: https://lnkd.in/eHRSNgjpLearn more at www.crescentbiopharma.com.#SolidTumors #Oncology #CancerCare #Merger #Biotech
Excited to see our partners at Apogee Therapeutics have shared strong updated results for their Phase 1 trial of APG777 for the treatment of #AtopicDermatitis at the American College of Allergy, Asthma and Immunology (ACAAI) 2024 Annual Meeting. Read the full release below.
Today, we announced results up to 9 months from the Phase 1 trial of APG777 for the treatment of #atopicdermatitis, building on positive interim data from the trial announced in March. These data continue to support a potential best-in-class PK and PD profile of APG777, and in particular, a near-complete inhibition of pSTAT6 and sustained TARC inhibition out to 9 months following a single dose. Read highlights from this data being presented at #ACAAI24 below, and find more in the press release here. https://lnkd.in/eKHjZXCR
Congrats to Oruka Therapeutics on their recent public listing on NASDAQ—an exciting milestone on their path to improve treatment for patients living with plaque psoriasis, psoriatic arthritis, and other dermatologic and inflammatory indications!
We recently celebrated our public listing at the Nasdaq MarketSite in Times Square! We’re proud to mark this achievement along our path to develop novel biologics for plaque psoriasis and related conditions. Photography courtesy of Nasdaq, Inc.
Excited to see our partner Spyre Therapeutics accelerating their program, SPY003 (anti-IL-23), for the treatment of #IBD! The program is now expected to enter a Phase 1 clinical trial in 1Q25. Congratulations to the Spyre team on the new data presented at UEGW as well!
Today, we announced an acceleration of our third program, SPY003 (anti-IL-23), which is now expected to enter a Phase 1 clinical trial in Q1 2025. We also announced presentations of scientific posters this past weekend at the UEG - United European Gastroenterology Week (UEGW) Congress, including new data across our portfolio of next-generation antibodies and potentially paradigm-changing combination therapies. For more information, you can read the full news release and forward-looking statement legend here: https://lnkd.in/g6uKbiPbScientific posters can be viewed here: https://lnkd.in/gYpHiq2g #IBD #BioTech
We're proud to see the Oruka Therapeutics team share promising preclinical data on ORKA-001 suggesting its potential to improve dosing and help people living with #psoriasis achieve freedom from their condition. We look forward to celebrating future progress together!
We’re excited to present new preclinical data on ORKA-001, a novel extended half-life monoclonal antibody targeting IL-23p19, at the EADV Congress in Amsterdam. The data show that ORKA-001 has a three-fold longer half-life in non-human primates than risankizumab, while binding to a similar epitope with similar affinity. These findings give us additional confidence that ORKA-001 can achieve our base-case expectation of dosing once every six months and further reason to believe we could reach once-yearly dosing with the potential for higher efficacy, all with the goal of offering people with psoriasis the most possible freedom from their disease.
ORKA-001 EADV Poster ir.orukatx.com

Join now to see what you are missing

Join now